Biocon Ltd. (BIOCON) fundamentals
Biocon Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as BIOCON (ISIN INE376G01013). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Biocon Ltd. does
Biocon Limited is an India-based biopharmaceutical company, engaged in the manufacture of biotechnology products and research services. The Company is in the business of manufacturing active pharmaceutical ingredients (APIs) and formulations, including biosimilar drugs for diabetics, oncology and autoimmune diseases. The Company’s segment includes Generics, Biosimilars, Novel Biologics and Research Services. It focuses on three key therapeutic areas - Oncology, Diabetes, and Immunology. Its APIs portfolio includes cardiovascular, anti-diabetics, immunosuppressants, and specialty molecules. Its products include Tacrolimus, Rosuvastatin, Simvastatin, Atorvastatin, Pravastatin, Fingolimod and others. Its APIs manufacturing facilities with capabilities in microbial fermentation, downstream process, including chromatographic purification, chemical synthesis, peptide synthesis and Highly Potent APIs (HPAPIs). It has over five facilities in Bangalore, Hyderabad and Visakhapatnam in India.
Valuation and market data
| Last close | ₹390.65 |
|---|---|
| Market capitalisation | ₹51,089 crore |
| Enterprise value | ₹61,938 crore |
| P/E (TTM) | 138.53 |
| Price to book | 1.40 |
| Price to sales (TTM) | 1.70 |
| Book value per share | ₹280.02 |
| Dividend yield | 12.80% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Wed Apr 07 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹17,270 crore | ₹448 crore | ₹369 crore | 2.82 |
| Mar 2025 | ₹16,470 crore | ₹1,887 crore | ₹1,429 crore | 8.46 |
| Mar 2024 | ₹15,621 crore | ₹1,525 crore | ₹1,298 crore | 8.55 |
| Mar 2023 | ₹11,550 crore | ₹897 crore | ₹643 crore | 3.88 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 44.7% |
|---|---|
| Foreign institutions (FII) | 8.1% |
| Mutual funds | 15.5% |
| Other domestic institutions | 7.9% |
| Retail and others | 23.8% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.